Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRx-139 plus DMARD versus steroid plus DMARD in active rheumatoid arthritis
2004-004995-35Phase 2Completed
- Sponsor
- CombinatoRx
- Start
- Mar 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of paroxetine + prednisolone, prednisolone and paroxetine in rheumatoid arthritis (RA) (3 arms), sponsored by CombinatoRx. Primary endpoint: ACR20 response at 8 weeks. Started Mar 2005; status: completed.
02
Drugs
paroxetine + prednisoloneprednisoloneparoxetine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2004-004995-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004995-35.